Joshua J. Skydel

Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics

Tanvee Varma, Joshua D. Wallach, Jennifer Miller et al. · JAMA Network Open · 2021 · 41 citations · Full text

Publishing at any cost: a cross-sectional study of the amount that medical researchers spend on open access publishing each year

Mallory K. Ellingson, Xiaoting Shi, Joshua J. Skydel et al. · BMJ Open · 2021 · 27 citations · Full text

Characteristics and Reporting of Number Needed to Treat, Number Needed to Harm, and Absolute Risk Reduction in Controlled Clinical Trials, 2001-2019

Marissa H. Elliott, Joshua J. Skydel, Sanket S. Dhruva et al. · JAMA Internal Medicine · 2020 · 23 citations · Full text

Early Goals-of-care Discussions, Important Limitations, Harm Reduction +27

Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval

Joshua D. Wallach, Audrey D. Zhang, Joshua J. Skydel et al. · JAMA Network Open · 2021 · 23 citations · Full text

US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009–2018

Joshua J. Skydel, Audrey D. Zhang, Sanket S. Dhruva et al. · Clinical Trials · 2021 · 22 citations · Full text